Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.34 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15520638 | 0.88 | CHEK1 (0.41) | CHEK1FFAR1F7PPARGKDM4E | |
| SCHEMBL15520025 | 0.87 | CHEK1 (0.42) | CHEK1FFAR1F7PPARGKDM4E | |
| SCHEMBL16616778 | 0.85 | HDAC6 (0.40) | CHEK1FFAR1F7ALDH1A1SLC2A1 | |
| SCHEMBL16617371 | 0.85 | F7 (0.42) | CHEK1FFAR1F7KDM4EALDH1A1 | |
| SCHEMBL15520107 | 0.80 | CHEK1 (0.36) | CHEK1EGFRFFAR1F7PPARG | |
| SCHEMBL15520722 | 0.80 | CHEK1 (0.44) | CHEK1FFAR1MAPT | |
| SCHEMBL15520684 | 0.77 | CHEK1 (0.42) | CHEK1FFAR1PPARGKDM4EFFAR4 | |
| SCHEMBL15520108 | 0.77 | TLR7 (0.36) | CHEK1EGFRFFAR1PPARGKDM4E | |
| SCHEMBL15520164 | 0.75 | CHEK1 (0.40) | CHEK1FFAR1PPARGKDM4EALDH1A1 | |
| SCHEMBL15520769 | 0.75 | CHEK1 (0.40) | CHEK1FFAR1F7PPARGFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD. (GB) | 2020-06-30 | — | — | US | disclosed |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2018-08-30 | — | — | US | disclosed |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | disclosed |
| US-8916591-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2014-12-23 | — | — | US | disclosed |
| EP-2294065-B1 | INDOLYL-PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS R&D LTD (GB) | 2014-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | CHEK1 1/4885EGFR 147/4885FFAR1 1624/4885 |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | CHEK1 2/4885EGFR 599/4885FFAR1 4072/4885 |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | CHEK2, CHEK1, BUB1B | CHEK1 2/4885EGFR 599/4885FFAR1 4072/4885 |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | CHEK1 2/4885EGFR 599/4885FFAR1 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.